Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
KROS Keros Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: KROS
Price (delayed)
$14.07
Market cap
$571.46M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.12
Enterprise value
-$132.12M
Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with high unmet medical need. Keros
Highlights
The company's net income has surged by 103% YoY and by 102% QoQ
KROS's EPS has surged by 98% year-on-year and by 98% since the previous quarter
The debt has grown by 30% YoY but it has contracted by 2.4% from the previous quarter
The quick ratio has contracted by 21% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of KROS
Market
Valuations
Earnings
Shares outstanding
40.62M
Market cap
$571.46M
Enterprise value
-$132.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.78
Price to sales (P/S)
2.66
EV/EBIT
-9.08
EV/EBITDA
-7.37
EV/Sales
-0.62
Revenue
$214.71M
Gross profit
$214.71M
Operating income
-$10.31M
Net income
$4.21M
EBIT
$14.56M
EBITDA
$17.92M
Free cash flow
$43.31M
Per share
Balance sheet
Liquidity
EPS
-$0.12
EPS diluted
-$0.16
Free cash flow per share
$1.07
Book value per share
$17.97
Revenue per share
$5.29
TBVPS
$19.34
Total assets
$784.56M
Total liabilities
$55.69M
Debt
$18.41M
Equity
$728.87M
Working capital
$720.13M
Debt to equity
0.03
Current ratio
19.29
Quick ratio
18.77
Net debt/EBITDA
-39.27
Margins
Efficiency
Dividend
EBITDA margin
8.3%
Gross margin
100%
Net margin
2%
Operating margin
-4.8%
Return on assets
0.7%
Return on equity
0.7%
Return on invested capital
35.2%
Return on capital employed
2%
Return on sales
6.8%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
KROS stock price
How has the Keros Therapeutics stock price performed over time
Intraday
0.29%
1 week
3.08%
1 month
3.99%
1 year
-73.94%
YTD
-11.12%
QTD
38.08%
Financial performance
How have Keros Therapeutics's revenue and profit performed over time
Revenue
$214.71M
Gross profit
$214.71M
Operating income
-$10.31M
Net income
$4.21M
Gross margin
100%
Net margin
2%
The company's net income has surged by 103% YoY and by 102% QoQ
The net margin has soared by 100% from the previous quarter and by 100% YoY
The operating margin has surged by 100% year-on-year and by 100% since the previous quarter
Keros Therapeutics's operating income has soared by 95% from the previous quarter and by 94% YoY
Price vs fundamentals
How does KROS's price correlate with its fundamentals
Growth
What is Keros Therapeutics's growth rate over time
Valuation
What is Keros Therapeutics stock price valuation
P/E
N/A
P/B
0.78
P/S
2.66
EV/EBIT
-9.08
EV/EBITDA
-7.37
EV/Sales
-0.62
KROS's EPS has surged by 98% year-on-year and by 98% since the previous quarter
The price to book (P/B) is 81% lower than the 5-year quarterly average of 4.2 and 68% lower than the last 4 quarters average of 2.4
KROS's equity has surged by 61% year-on-year and by 28% since the previous quarter
KROS's P/S is 100% below its last 4 quarters average of 2402.6
Efficiency
How efficient is Keros Therapeutics business performance
The ROIC has soared by 108% from the previous quarter and by 107% YoY
The company's return on assets has surged by 102% QoQ and by 102% YoY
The ROE has soared by 102% from the previous quarter and by 102% YoY
KROS's return on sales has surged by 100% since the previous quarter and by 100% year-on-year
Dividends
What is KROS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for KROS.
Financial health
How did Keros Therapeutics financials performed over time
The total liabilities has surged by 75% year-on-year and by 26% since the previous quarter
KROS's total assets has soared by 61% YoY and by 27% QoQ
The debt is 97% less than the equity
KROS's equity has surged by 61% year-on-year and by 28% since the previous quarter
The debt has grown by 30% YoY but it has contracted by 2.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.